Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Share-based Compensation (2021 - 2025)

Amylyx Pharmaceuticals has reported Share-based Compensation over the past 5 years, most recently at $6.4 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $6.4 million for Q4 2025, down 5.27% from a year ago — trailing twelve months through Dec 2025 was $27.6 million (down 16.32% YoY), and the annual figure for FY2025 was $27.6 million, down 16.32%.
  • Share-based Compensation for Q4 2025 was $6.4 million at Amylyx Pharmaceuticals, down from $7.1 million in the prior quarter.
  • Over the last five years, Share-based Compensation for AMLX hit a ceiling of $10.2 million in Q3 2023 and a floor of $586000.0 in Q1 2021.
  • Median Share-based Compensation over the past 5 years was $6.8 million (2024), compared with a mean of $6.1 million.
  • Biggest five-year swings in Share-based Compensation: soared 768.65% in 2022 and later plummeted 33.15% in 2024.
  • Amylyx Pharmaceuticals' Share-based Compensation stood at $1.1 million in 2021, then surged by 458.3% to $6.1 million in 2022, then surged by 56.53% to $9.5 million in 2023, then fell by 29.3% to $6.7 million in 2024, then dropped by 5.27% to $6.4 million in 2025.
  • The last three reported values for Share-based Compensation were $6.4 million (Q4 2025), $7.1 million (Q3 2025), and $7.4 million (Q2 2025) per Business Quant data.